Cleveland Clinic | Strategic Alliance Partners

September 24, 2019

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses challenges with biomarkers in renal cell carcinoma (RCC).

August 16, 2019

Jame Abraham, MD, director of the Breast Oncology Program at Taussig Cancer Institute, co-director of the Cleveland Clinic Comprehensive Breast Cancer Program, and professor of medicine, Cleveland Clinic Lerner College of Medicine, discusses improving access to cancer therapy with biosimilars.

July 16, 2019

Brian T. Hill, MD, PhD, highlights the latest data with BTK inhibitors in chronic lymphocytic leukemia.

July 04, 2019

Davendra Sohal, MD, MPH, discusses the SWOG S1505 trial, which looks at initial findings on eligibility and neoadjuvant chemotherapy experience with mFOLFIRINOX versus gemcitabine/nab-paclitaxel for resectable pancreatic adenocarcinoma.

May 23, 2019

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses managing the toxicity of pembrolizumab plus axitinib in patients with metastatic renal cell carcinoma.

April 24, 2019

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the combination of pembrolizumab plus axitinib in the treatment of patients with metastatic renal cell carcinoma.

April 16, 2019

Investigators at Cleveland Clinic have demonstrated that the direct oral anticoagulant rivaroxaban significantly reduces venous thromboembolism (VTE) and VTE-related death for patients with high-risk cancers treated in the outpatient setting.

March 02, 2019

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the potential for tivozanib in patients with advanced renal cell carcinoma.

February 21, 2019

Cleveland Clinic research has found that the blood thinner rivaroxaban significantly reduces venous thromboembolism (VTE)—a blood clot in the venous system—and VTE-related death for outpatient, high-risk cancer patients while they are taking the oral anticoagulant.

February 06, 2019

Jason Valent, MD, an oncologist at Cleveland Clinic, discusses ongoing research with immunotherapy, specifically checkpoint inhibitors, in the treatment of patients with multiple myeloma.

January 19, 2019

Robert Dean, MD, staff physician, Cleveland Clinic, discusses challenges in the mantle cell lymphoma (MCL) paradigm.

January 16, 2019

Brian T. Hill, MD, PhD, assistant professor, Hematology and Oncology, Cleveland Clinic, discusses resistance to BTK inhibition in chronic lymphocytic leukemia (CLL).

January 04, 2019

Robert Dean, MD, staff physician, Cleveland Clinic, discusses FDA approved drugs for patients with relapsed mantle cell lymphoma.

November 27, 2018

Robert Dean, MD, a staff physician at Cleveland Clinic, discusses ongoing research on biomarkers in mantle cell lymphoma (MCL).

November 14, 2018

Robert Dean, MD, discusses the promise for new therapies in mantle cell lymphoma.

November 08, 2018

Brian T. Hill, MD, PhD, assistant professor, Hematology and Oncology, Cleveland Clinic, discusses the progression of treatment of patients with chronic lymphocytic leukemia.

November 07, 2018

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the molecular characteristics of patients with renal cell carcinoma (RCC) enrolled on the IMmotion151 study.

November 06, 2018

The VEGF inhibitor tivozanib reduced the risk of disease progression or death by 26% compared with sorafenib in patients with highly refractory advanced or metastatic RCC, according to topline findings from the phase III TIVO-3 trial.

November 06, 2018

Jason Valent, MD, an oncologist at Cleveland Clinic, discusses the recent FDA approval of dose-adjusted carfilzomib in patients with myeloma.

November 05, 2018

Based on fresh studies in the setting of metastatic pancreatic cancer, the American Society of Clinical Oncology now recommends routine testing for mismatch repair deficiency or high microsatellite instability for candidates for checkpoint inhibitor therapy.